TAmiRNA operates a fully developed research and development laboratory for automated high-throughput screening of microRNAs expression from virtually any biological source including cells, tissues and biofluids. TAmiRNA has further developed protocols for the isolation of microvesicles and RNA from various biofluids and tissues. A robust RNA profiling platform allows high throughput screening of full miRNome (~ 2000 microRNAs) down to specific sets of microRNAs. For this purpose TAmiRNA has implemented locked-nucleic-acid (LNA) based qPCR technologies developed by Exiqon A/S, as well as next-generation sequencing technologies. For testing the biological function of microRNAs, various molecular biology tools and in vitro bioassays have been developed in collaboration with the Grillari Labs and Evercyte. In collaborations with biostatisticians, bioinformaticians, and epidemiologists we achieve to identify and validate microRNA biomarkers with utility for diagnosis, prognosis, treatment monitoring and drug development.
The main interest of TAmiRNA is the development of novel diagnostic tests to improve the management of musculoskeletal and cardiovascular disorders. Therefore, TAmiRNA actively seeks to identify biomarker panels, which can be used to predict fracture risk in post-menopausal women and aged men. This osteomiRTM test - will enable a better decision process for treating osteoporosis and preventing severe low-trauma fractures. In addition we are constantly looking to expand or product and technology pipeline through in-licensing of intellectual property from academia and industry.